Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Celltrion, Inc.    068270   KR7068270008

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( KRW)
Sales 2017 874 B
EBIT 2017 398 B
Net income 2017 312 B
Debt 2017 283 B
Yield 2017 0,31%
Sales 2018 1 163 B
EBIT 2018 557 B
Net income 2018 449 B
Debt 2018 151 B
Yield 2018 0,45%
P/E ratio 2017 37,41
P/E ratio 2018 26,34
EV / Sales2017 13,7x
EV / Sales2018 10,1x
Capitalization 11 647 418 M
More Financials
Company
Celltrion, Inc. engages in the development, manufacture, and distribution of pharmaceuticals.It operates through the Biopharmaceuticals, Chemical Drugs, and Others businesses.Its products include remsima and biosimilars.The company was founded on February 27, 1991 and is headquartered in Incheon,... 
More about the company
Surperformance© ratings of Celltrion, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on CELLTRION, INC.
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
04/28 Celltrion wins Herceptin patent trials against Roche in Korea
04/07 CELLTRION : George Steuart Health partners with Celltrion Healthcare to launch f..
03/02 CELLTRION : Patent Issued for Human Monoclonal Antibodies Derived from Human B C..
02/20 PFIZER : Celltrion Healthcare & Pfizer’s biosimilar shows positive results..
2016 CELLTRION : New statement from European Crohn's and Colitis Organisation support..
2016 CELLTRION HEALTHCARE : Presents Positive Results for CT-P10, Biosimilar Rituxima..
2016 MONOCLONAL ANTIBODIES MARKET 2016-20 : Celltrion, Boehringer Ingelheim, Dr Reddy..
2016 CELLTRION HEALTHCARE : Showcases Data Supporting Efficacy and Safety of Both CT-..
2016 Pfizer to start shipping biosimilar version of J&J's Remicade in November
More news
Sector news : Biotechnology & Medical Research - NEC
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 127 465  KRW
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Wu-Sung Ki Co-Chief Executive Officer & Director
Hyung-Ki Kim Co-Chief Executive Officer & Director
Jung-Jin Seo Director
Dong-Il Kim Outside Director
Gyung-Ho Lee Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.10 254
INCYTE CORPORATION37.73%27 528
QUINTILES IMS HOLDINGS..10.19%18 382
LONZA GROUP AG23.08%15 234
SEATTLE GENETICS, INC.26.34%9 492
ALKERMES PLC3.83%8 934
More Results